Literature DB >> 6616469

Stability, characterization, and kinetics of 111In-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models.

S E Halpern, P L Hagan, P R Garver, J A Koziol, A W Chen, J M Frincke, R M Bartholomew, G S David, T H Adams.   

Abstract

Monoclonal antibodies (MoAbs) against carcinoembryonic antigen were successfully radiolabeled with 111In, and the radiopharmaceutical was characterized in vitro and in normal and tumor-bearing mice. The 111In-MoAb proved to be stable in vitro and in vivo under normal conditions, although instability could be induced in vitro with large quantities of iron-free transferrin. Animal distribution studies with 111In-MoAb demonstrated tumor localization superior to 67Ga and pharmacokinetics that were highly similar to those of endogenously labeled 75Se-MoAb. The 111In-MoAb followed first-order kinetics and fit a two-compartmental model when studied in nude mice bearing human colon tumors known to express carcinoembryonic antigen. Significant quantities of radiolabel appeared in tissues other than tumor, with liver and skin having the highest concentrations. Sufficient tumor/background ratios were formed for scanning purposes. The data indicate that 111In-MoAb may prove to be effective as a radiopharmaceutical for tumor imaging.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  A comparative distribution study of 111In-labeled DTPA and TTHA monoclonal antibody conjugates in a choriocarcinoma xenograft model.

Authors:  R G Buckley; P Barnett; F Searle; R Pedley; J A Boden
Journal:  Eur J Nucl Med       Date:  1986

3.  Radioimmunotherapy: no news from the newcomer.

Authors:  A M Mello; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period.

Authors:  S E Halpern; R Bartholomew
Journal:  Eur J Nucl Med       Date:  1995-11

5.  Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. II. Biodistribution studies in mice with human tumour xenografts.

Authors:  M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1985

6.  A comparison of iodine and indium labelled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts.

Authors:  S M Andrew; A C Perkins; M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1988

7.  A preliminary pharmacokinetic study of 111In-labeled 260F9 anti-(breast cancer) antibody in patients.

Authors:  T W Griffin; F Bokhari; J Collins; M Stochl; M Bernier; M Gionet; D Siebecker; M Wertheimer; E S Giroves; L Greenfield
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies.

Authors:  M G Rosenblum; J L Murray; L Lamki; G David; D Carlo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Comparative biodistributions and rates of catabolism of radiolabelled anti-CEA monoclonal antibody and control immunoglobulin in nude mice with human tumour xenografts showing specific antibody localization.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1987

10.  Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium.

Authors:  D Buchsbaum; B Randall; D Hanna; R Chandler; M Loken; E Johnson
Journal:  Eur J Nucl Med       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.